Academic Journal
Q1mAbs
About mAbs
mAbs is a scholarly journal published by Taylor and Francis Ltd.. SCImago 2025 lists it in Q1, with an SJR of 2.065 and H-index of 117.
Coverage: 2009-2026. Research categories: Immunology (Q1); Immunology and Allergy (Q1).
Open-access policies and author information
Reported in the official DOAJ public CSV snapshot (2026-09-01), downloaded 2026-10-03. Record updated 2024-08-08. This snapshot does not establish today’s listing status or fee quotation.
Publisher policy links recorded by DOAJ
- Aims and scope ↗
- Editorial board ↗
- Instructions for authors ↗
- Peer-review policy ↗
- Publication fees ↗
- Fee waivers ↗
- Licence terms ↗
- Copyright policy ↗
- Preservation policy ↗
Source: DOAJ journal record. Journal metadata is distributed by DOAJ under CC0. Confirm current fees, tax, eligibility and waiver terms with the publisher.
Source-backed journal facts
Topics in published research
Monoclonal and Polyclonal Antibodies Research; Protein purification and stability; Glycosylation and Glycoproteins Research; Viral Infectious Diseases and Gene Expression in Insects; CAR-T cell therapy research; Biosimilars and Bioanalytical Methods.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
NanoSaurus: addressing the urgent need for open access in single-domain antibody research
P. Di Filippo, E. Pardon, R.J. Owens, F.I. Schmidt et al.
2026-12-31 · DOI: 10.1080/19420862.2026.2733370Near pan-alphavirus neutralization by an antibody-nanobody bispecific
Sergei Pletnev, Christina L. Gardner, Matthew S. Sutton, Baoshan Zhang et al.
2026-12-31 · DOI: 10.1080/19420862.2026.2731281Predicting non-specific binding of VHHs using machine learning models with cluster-aware validation
Valentin Stanev, Federico Devalle, Mehdi Boroumand, Maryam Pouryahya et al.
2026-12-31 · DOI: 10.1080/19420862.2026.2732787A framework for evaluating unexpected reactions in antibody-drug conjugates during clinical development: a case study of a promiscuous payload
Eef H. C. Dirksen, Marijn Buurman, Jeroen Kooistra, Benno Ingelse et al.
2026-12-31 · DOI: 10.1080/19420862.2026.2732607Discovery and engineering of bispecific TCR-mimic antibodies targeting peptide–HLA complex
Jennifer Watkins-Yoon, Wei-Cheng Lu, Elyse M. Petrunak, Noah J. Tubo et al.
2026-12-31 · DOI: 10.1080/19420862.2026.2731282Correction
2026-12-31 · DOI: 10.1080/19420862.2026.2728528Preclinical development of ABL206, a novel bispecific antibody-drug conjugate targeting B7-H3 and ROR1
Jung A. Kwon, Suyoun Lee, Juhee Kim, Byeong Min Yoo et al.
2026-12-31 · DOI: 10.1080/19420862.2026.2731283HDX-MS-Guided computational modeling for rapid and accurate antibody-antigen interface mapping
Will McMahon, Hanzhi Zhang, Xiuling Li, Vaheh Oganesyan et al.
2026-12-31 · DOI: 10.1080/19420862.2026.2722455Antibody framework engineering enables augmented cytokine receptor signaling capacities of bispecific single domain antibody-based IL-21 mimetics
Britta Lipinski, Laura Unmuth, Thi Hong Hue Tran, Jakob Harwood et al.
2026-12-31 · DOI: 10.1080/19420862.2026.2726042Generation of a highly versatile TCR bispecific scaffold optimized for targeting tumor-specific peptide-HLA antigens
Martin Hofmann, Felix Unverdorben, M. Gabriele Pszolla, Nadine Aschmoneit et al.
2026-12-31 · DOI: 10.1080/19420862.2026.2722707Artificial intelligence-assisted design of MAGE-A4 ×CD16 T-cell receptor-like natural killer cell engagers
Yang Liu, Hongsen Peng, Xing Fan, Xiaoxi Liu et al.
2026-12-31 · DOI: 10.1080/19420862.2026.2717991Quantifying molecular specificity in excipient-driven antibody solubilization
Zexiang Han, Nadia A. Erkamp, Rob Scrutton, Giuseppe Licari et al.
2026-12-31 · DOI: 10.1080/19420862.2026.2722444DyAb: sequence-based antibody design and property prediction in a low-data regime
Joshua Yao-Yu Lin, Jennifer L. Hofmann, Andrew Leaver-Fay, Wei-Ching Liang et al.
2026-12-31 · DOI: 10.1080/19420862.2026.2717460Efficient brain delivery and sustained retention of antibodies via dual targeting of blood–brain barrier and intra-brain proteins
Yuki Noguchi, Naoka Hironiwa, Kazuki Sato, Masaki Yamazaki et al.
2026-12-31 · DOI: 10.1080/19420862.2026.2724587AlphaFold 3 prediction of TCR mimic Fv – pMHC complex structures and their validation and optimization
Abhijit Sarkar, Sara Michael, Zening Wang, Xin Ge et al.
2026-12-31 · DOI: 10.1080/19420862.2026.2719263Design and preclinical characterization of an affinity-tuned BCMA×CD3 bispecific T-cell engager for broad B-cell depletion
Jamie Thomas, Gang Xu, Hannah Lock, Qin Song et al.
2026-12-31 · DOI: 10.1080/19420862.2026.2718587Mimic antibodies: leveraging ligand mimicry for epitope-targeted antibody discovery
Brennan Abanades, Joanan Lopez-Morales, Ivan Tanasijevic, Cornelia Wagner et al.
2026-12-31 · DOI: 10.1080/19420862.2026.2719289Local electrostatics governs tryptophan oxidation and enables rational stability engineering in antibodies
Sunidhi Lenka, Shrenik Mehta, Nicole Stephens, Franziska Seeger et al.
2026-12-31 · DOI: 10.1080/19420862.2026.2713231JMB2403, a potential best-in-class PD-1-dependent IL2Rβγ-activating tri-specific antibody for safe and potent immunotherapy
Chunyin Gu, Deyi Wang, Yan Wang, Fangfang Jia et al.
2026-12-31 · DOI: 10.1080/19420862.2026.2709956Self-interaction nanoparticle spectroscopy predicts high-concentration viscosity of therapeutic IgG1 antibodies
Santosh Kumar Paidi, Julissa Ibrahim, Kateryna Stepurska, Jonathan Zarzar et al.
2026-12-31 · DOI: 10.1080/19420862.2026.2709948Reviews
Community Reviews
Version History
September 25, 2026 at 7:10 am
September 25, 2026